Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype

Launched by THE AFFILIATED NANJING DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL · Jun 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of two different combinations of medications for patients with unruptured intracranial aneurysms, which are bulges in blood vessels in the brain that haven’t yet burst. Specifically, it compares aspirin mixed with clopidogrel to aspirin mixed with a lower dose of ticagrelor to see which combination works better at preventing blood clots in these patients. The researchers will also look at any side effects participants might experience while taking these medications.

To participate in the trial, individuals must be between 20 and 70 years old, have a specific genetic profile (normal CYP2C19 metabolizer), and be scheduled for a particular type of brain surgery called stent-assisted embolization. Participants will take one of the medication combinations daily for six months and will need to visit the clinic for checkups at one month and six months after starting the treatment. This study aims to help doctors better understand how to treat patients with these aneurysms safely and effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with unruptured intracranial aneurysms who are scheduled for stent-assisted embolization;
• • 2. mRS score less than or equal to 2 on admission;
• • 3. Normal CYP2C19 metabolizer genotype;
• • 4. Age 20 or above, 70 or below, regardless of gender;
• • 5. The subject or the entrusted family member voluntarily signed the informed consent for this trial
• Exclusion Criteria:
• • 1. Use of drugs that affect coagulation function or significant abnormalities in platelet/coagulation function before admission;
• • 2. Previous history of cardiovascular and cerebrovascular disease;
• • 3. Complications of major organ dysfunction, chronic inflammatory diseases or malignant tumors at admission;
• • 4. Known allergy or contraindication to heparin, aspirin, clopidogrel, or ticagrelor;
• • 5. Patients with any severe or active pathological bleeding;
• • 6. Pregnant and lactating female;
• • 7. Those deemed unsuitable to participate in this trial by the responsible physician